|
NYBA News |
Member News
|
Press Release
|
| |
|
|
News type
|
|
Amgen, Inc. |
|
Headline:
Amgen Scientists Visit Biotechnology Classrooms Across the Country in Support of National Lab Day
Scientists Will Engage with Students Participating in the Amgen-Bruce Wallace Biotechnology Lab Program
Date:
06-May-2010
News Type:
Member News
Answering the call from President Obama to reinvigorate science and math education by
connecting students to hands-on learning experiences, Amgen scientists will visit high
schools that include the Amgen-Bruce Wallace Biotechnology Lab Program in their science
curriculum. In conjunction with National Lab Day, the visits will give students a
first-hand perspective on how the very sa ...
Details »
|
|
| |
|
Acorda Therapeutics, Inc |
|
Headline:
Acorda Therapeutics Chief Executive Officer Ron Cohen Elected Chairman of BIO Emerging Companies Section
Date:
04-May-2010
News Type:
Member News
Acorda Therapeutics, Inc.(Nasdaq: ACOR) today announced that Ron Cohen, M.D., President
and CEO, has been elected chairman of the Biotechnology Industry Organization (BIO)
Emerging Companies Section. The Emerging Companies Section serves the needs of small and
medium size BIO member companies, most of whom do not yet have major products approved and
on the market. Members of the group examine issu ...
Details »
|
|
| |
|
EpiCept Corporation |
|
Headline:
EpiCept Earns $2 Million Milestone Payment from Meda AB
Date:
04-May-2010
News Type:
Member News
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that
it has earned a $2 million milestone payment from Meda AB, (OMX Nordic Exchange:
MEDA-A-ST), for the first commercial shipment of Ceplene(R) (histamine dihydrochloride) to
a major country in the European Union, as defined in the agreement. The milestone payment
is part of an exclusive commercial licensing agr ...
Details »
|
|
| |
|
Bristol-Myers Squibb Company |
|
Headline:
Bristol-Myers Squibb Announces Authorization of Up to $3 Billion Share Repurchase Program
Date:
04-May-2010
News Type:
Member News
Bristol-Myers Squibb Company (NYSE: BMY) today announced its Board of Directors has
authorized the repurchase of up to $3 billion of its common stock.
The decision reflects the Company’s strong financial position, including cash and
marketable securities of $9.8 billion at the end of the first quarter, its positive
outlook on its future cash position, and its focus on increas ...
Details »
|
|
| |
|
Bristol-Myers Squibb Company |
|
Headline:
Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept
Date:
01-May-2010
News Type:
Member News
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug
Administration (FDA) has issued a complete response letter regarding the Biologics License
Application for belatacept in kidney transplantation.
“Bristol-Myers Squibb is committed to belatacept as a potential new therapeutic
option for kidney transplant patients” ...
Details »
|
|
| |
|
OSI Pharmaceuticals Inc. |
|
Headline:
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Date:
29-Apr-2010
News Type:
Member News
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner
for Tarceva(R) (erlotinib), Roche, received approval from the European Commission for
Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell
lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after
platinum-based initial chemotherapy.
&q ...
Details »
|
|
| |
|
Bristol-Myers Squibb Company |
|
Headline:
New Data on the Use of Investigational Agent Belatacept in Kidney Transplant Recipients to Be Presented at 2010 American Transplant Congress
Date:
28-Apr-2010
News Type:
Member News
Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an
investigational selective T cell co-stimulation blocker being studied for use in solid
organ transplantation, will be the subject of eight clinical presentations related to
kidney transplantation at the American Transplant Congress, being held May 1 – 5 in
San Diego. Belatacept, which received a positive U.S. Food an ...
Details »
|
|
| |
|
Amgen, Inc. |
|
Headline:
Amgen Appoints Robert A. Bradway President and Chief Operating Officer
Date:
27-Apr-2010
News Type:
Member News
Amgen (Nasdaq: AMGN) today announced that the Board of Directors has appointed Robert A.
Bradway president and chief operating officer (COO), effective May 11. In this new role,
Bradway will report to Kevin Sharer, Amgen's chairman and chief executive officer, and
will be responsible for the company's Global Commercial Operations, Manufacturing
Operations, Strategy & Corporate Development, Inf ...
Details »
|
|
| |
|
OSI Pharmaceuticals Inc. |
|
Headline:
OSI Pharmaceuticals Announces That "RADIANT", an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung Cancer, Completes Enrollment
Date:
26-Apr-2010
News Type:
Member News
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment
in the RADIANT study, a Phase III clinical trial testing Tarceva(R) (erlotinib) as an
adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer (NSCLC) who
have undergone surgery and have EGFR-positive tumors. RADIANT is an international,
randomized, double-blinded, placebo-controlled Phase I ...
Details »
|
|
| |
|
Acorda Therapeutics, Inc |
|
Headline:
Acorda Therapeutics Chief Scientific Officer Andrew R. Blight Receives Purchase College Science Entrepreneurship Award
Date:
26-Apr-2010
News Type:
Member News
Acorda Therapeutics, Inc.(Nasdaq: ACOR) today announced that Andrew R. Blight, Ph.D.,
Chief Scientific Officer, is the recipient of the Inaugural Purchase College Scientific
Entrepreneurship Award. The award recognizes individuals for their scientific excellence,
ability to integrate science with business, vision and innovation, social responsibility
and providing a positive role model for future ...
Details »
|
|
| |
|
|
